
About
CN Bio develops organ-on-a-chip and microphysiological systems for human-relevant drug discovery, safety toxicology, and ADME studies. It provides in vitro contract research services and products to biopharma and research teams working on disease modeling, translational pharmacology, and preclinical decision-making. The company is based in Cambridge, UK, and serves customers through global distributors and direct contact in the UK and US.
Services
In vitro services
Standard and bespoke organ-on-a-chip contract research studies designed around customer goals to generate actionable data.
Assays & in vitro testing
MASH in vitro services
Human-relevant liver-on-a-chip studies for evaluating anti-MASH therapeutics, fibrosis, steatosis, inflammation, and cell health biomarkers.
Assays & in vitro testing
Drug-induced liver injury (DILI) in vitro services
Hepatotoxicity studies using Liver-on-a-chip models to assess human DILI risk, cross-species differences, and multiple liver health endpoints.
Assays & in vitro testing
ADME services
In vitro studies to investigate drug metabolism, metabolite identification, permeability, and bioavailability using organ-on-a-chip models.
Assays & in vitro testing
PhysioMimix Core
Microphysiological system hardware used to recreate complex human biology with organ-on-a-chip workflows.
Consumables
Multi-chip plate consumables for PhysioMimix organ-on-a-chip studies.
Organ-on-a-chip models
Single-organ and multi-organ models including liver, lung, and gut/liver systems.
Support packages
Support services for users of PhysioMimix technology.
- Turnaround
- Within weeks
- What to send
- Customer supplies required amount of drug(s)
Capabilities
- Assays and studies
- ADME · Toxicology · In vivo · Antibodies · Small molecules · Rodent models · Fibrosis assays · Steatosis assays · Inflammation assays · Hepatotoxicity assays · Drug metabolism assays · Metabolite identification
4 more
Permeability assays · Bioavailability prediction · CYP induction/inhibition · Drug-drug interaction studies - Therapeutic areas
- Metabolic dysfunction-associated steatohepatitis · Drug-induced liver injury · Immune-mediated liver injury · Hepatitis B · Pulmonary infection · Drug absorption · Drug metabolism · Drug bioavailability
Instruments and platforms
- PhysioMimix Core
- PhysioMimix multi-chip plates
Modalities and species
- Modalities
- Small molecule · Antibody · Oligonucleotide · Cell therapy · Gene editing
- Species and models
- Human · Rat · Dog · Liver-on-a-chip model · Lung-on-a-chip model · Gut/liver-on-a-chip model
Company
- Founded
- 2018
- Team
- 73% of employees are scientists or engineers
- Quality
- FDA ISTAND program (PhysioMimix technology accepted into FDA ISTAND) · FDA-recognized (PhysioMimix robustness, reliability, and enhanced performance over traditional approaches)
Locations
- Address
- 332 Cambridge Science Park, Milton Road Cambridge, CB4 0WN UK:
- Sites
- Cambridge, UK
- Serves
- UK, US, China, Australia, Japan, Korea
Similar labs
Work here? Claim this listing